Blue Cross Blue Shield of Mass. to cover Alzheimer's drug Leqembi
Blue Cross Blue Shield of Massachusetts initially balked at covering the treatment — which costs $26,500 per year per patient — because it considered Leqembi “investigational,” or experimental.